THIO Sequenced With Cemiplimab in Advanced NSCLC
Carcinoma, Non-Small-Cell Lung
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 227 (planned)
- Started
- Jun 8, 2022
- Main results expected
- Sep 30, 2027
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
Measured over: Up to 2 years
To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
Measured over: Up to 2 years
To assess the efficacy of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
Measured over: Up to 2 years
To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
Measured over: Up to 2 years
To determine the safety and tolerability of THIO administered in sequence with cemiplimab in subjects with advanced NSCLC
Measured over: Up to 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05208944 · record last updated 2026-09-16 · checked 2026-11-09 15:47 UTC